Case Report: Spatially fractionated radiation therapy for local recurrence after prior radiotherapy in advanced right-sided small cell lung cancer with mediastinal lymph node metastases - Report - MDSpire
Advertisement
Case Report: Spatially fractionated radiation therapy for local recurrence after prior radiotherapy in advanced right-sided small cell lung cancer with mediastinal lymph node metastases
Clinical Report: Use of Spatially Fractionated Radiation Therapy in SCLC
Overview
This case study presents a 63-year-old male with advanced right-sided small cell lung cancer who experienced local recurrence in mediastinal lymph nodes after prior treatments. The patient underwent Spatially Fractionated Radiation Therapy (SFRT) combined with atezolizumab, resulting in significant tumor regression and symptom relief.
Background
Lung cancer remains the leading cause of cancer-related mortality globally, with advanced stages often leading to severe complications such as airway compression and superior vena cava syndrome. Traditional treatments may be limited due to prior therapies and the complex anatomy of the mediastinum. SFRT offers a novel approach to enhance local tumor control while minimizing damage to surrounding healthy tissues.
Data Highlights
Parameter
Value
Tumor Volume Pre-SFRT
146 ml
Tumor Volume Post-SFRT
27 ml
Tumor Regression Rate
Over 80%
Total Dose of SFRT
30 Gy in 6 fractions
Key Findings
The patient had a significant reduction in tumor volume after SFRT.
SFRT was administered concurrently with atezolizumab, enhancing treatment efficacy.
No significant radiation-related adverse events were reported during or after treatment.
SFRT effectively relieved symptoms related to tracheal and superior vena cava compression.
This case highlights the potential of SFRT in managing recurrent mediastinal lymph node metastases in lung cancer.
Clinical Implications
The successful application of SFRT in this case suggests its potential role in treating local recurrences in advanced lung cancer, particularly when conventional therapies have failed. Clinicians may consider SFRT as a viable option for patients with similar profiles to improve outcomes and quality of life.
Conclusion
This case underscores the promise of SFRT in managing complex cases of recurrent small cell lung cancer, warranting further investigation into its long-term efficacy and broader applicability in clinical practice.
